Key Highlights
- Pacira (NASDAQ:PCRX) rose 44.07% to USD 36.30 after Viatris agreed to buy it for USD 36.50 per share in cash, about USD 1.65 billion, with closing expected by the end of 2026.
- Helen of Troy (NASDAQ:HELE) gapped up 22.62% on adjusted EPS of USD 0.79 and a raised outlook, then traded 8.12% below its open to end the snapshot up 12.87% at USD 28.79.
- Wolfspeed (NYSE:WOLF) gapped up 11.84% after a conditional USD 1.5 billion government loan commitment, then faded 5.94% from the open, leaving a 5.12% gain at USD 32.98 versus about 25% after hours.
- Haemonetics (NYSE:HAE) rose 15.89% to USD 117.87 after CSL said it expects to roll out its devices across all current US plasma centers by the end of calendar 2027, according to the company filing.
Pacira (NASDAQ:PCRX): A Cash Bid
Viatris announced on October 8, 2026 that it will acquire Pacira BioSciences for USD 36.50 per share in cash through a tender offer and second-step merger. The Equity value is about USD 1.65 billion, funded mainly from excess cash. The stock traded near USD 36.30, up 44.07%, which implies a prior close near USD 25.20, simple arithmetic, and leaves a spread of about 0.5% to the offer. That spread reflects timing and completion risk, since the deal needs a majority of shares tendered and expiry of the regulatory waiting period. Pacira (NASDAQ:PCRX) reported second quarter Revenue of USD 192.4 million, up 6%, and trimmed 2026 revenue guidance to USD 735 million to USD 760 million. Viatris discusses the deal on November 5, 2026 at 8:30 a.m. ET. Pacira sells EXPAREL, a long-acting numbing injection, and ZILRETTA for knee pain, and Viatris said it generated about USD 746 million of revenue and USD 177.0 million of adjusted EBITDA over the twelve months to June 30, 2026. Net Debt was about USD 112 million at that date, simple arithmetic on USD 363.1 million of debt and USD 251.0 million of cash, putting Enterprise value near USD 1.76 billion on mixed dates. No competing bid has been reported.
Helen of Troy (NASDAQ:HELE): A Beat That Faded
Helen of Troy released fiscal second quarter results on October 8, 2026 for the quarter ended August 31. Net sales rose 2.1% to USD 440.9 million, while adjusted EPS climbed 33.9% to USD 0.79 and gross Margin widened to 52.2% from 44.2%. About USD 0.12 of EPS came from net Tariff refunds, a one-time benefit. Management raised fiscal 2027 adjusted EPS guidance to USD 3.60 to USD 4.15 from USD 3.25 to USD 3.75 and cut its net Leverage target to 2.7 times or less. The stock opened about 22.6% above its implied prior close of USD 25.51, simple arithmetic, then sold off, which suggests buyers questioned how repeatable the beat is. Helen of Troy (NASDAQ:HELE) has not dated its next report. GAAP EPS was USD 0.19 versus a loss of USD 13.44 a year earlier, when USD 326.4 million of non-cash Impairment charges hit, and Operating Cash Flow was USD 57.1 million. Gross tariff refunds were USD 26.9 million, of which about USD 23 million was reinvested. The release did not explain the fade, so any reason is inference. Risks include tariffs and USD 4.0 million of divestiture litigation costs.
Wolfspeed (NYSE:WOLF): A Loan, Not Cash
After the close on October 7, 2026 Wolfspeed disclosed a conditional commitment letter for up to USD 1.5 billion of 30-year financing from the Office of Strategic Capital at the US Department of War, with warrants for up to 7.5% of its stock expected as agreements are finalized. After-hours prints showed gains of roughly 20% to 27% above the USD 31.37 close, but the stock gapped up only 11.84% on October 8 and then traded 5.94% below its open. Terms such as the rate and Collateral were not found, and Due Diligence is outstanding. Wolfspeed (NYSE:WOLF) reported a GAAP net loss of USD 145.4 million on revenue of USD 149.6 million last quarter and holds USD 1,088.6 million of cash. Its September quarter guidance was revenue of USD 140 million to USD 160 million with a negative non-GAAP gross margin, and long-term debt stood at USD 931.0 million. A government loan can fund capacity that private lenders may avoid but does not fix operating losses. The stock fell about 10.5% premarket on August 20, 2026 after its last report, so reactions run both ways. Watch for a filing on final terms.
Haemonetics (NYSE:HAE): A Bigger Rollout
Haemonetics furnished an 8-K on October 8, 2026 saying CSL Plasma expects to finish rolling out its NexSys PCS devices and disposables by the end of calendar 2027 and anticipates the transition at all of its current US plasma collection centers. The original August agreement is non-exclusive with no minimum purchase commitments, and no dollar value was disclosed. Haemonetics (NYSE:HAE) is not updating fiscal 2027 guidance until its November 5, 2026 call. The shares rose 15.89% to USD 117.87, implying a prior close near USD 101.71, simple arithmetic. In the quarter ended June 27, 2026, plasma revenue was USD 155.5 million of USD 339.4 million total revenue, up 5.6%. Haemonetics also raised fiscal 2027 guidance in August to reported revenue growth of 5% to 8%, and reported adjusted EPS of USD 1.14 with an adjusted Operating Margin of 23.4%. Plasma centers use devices that separate plasma and single-use disposables for each donation, so a device footprint can create recurring demand, but the agreement does not guarantee volumes. Watch the November 5 call for pricing and conversion pace.
Where Things Stand
Pacira (NASDAQ:PCRX) held its gap because a cash offer sets a price and the stock sits just below it. Helen of Troy (NASDAQ:HELE) gave back much of its opening gain. Wolfspeed (NYSE:WOLF) did the same, which shows how fragile moves built on one-time items or conditional headlines can be. Haemonetics (NYSE:HAE) rose on an unquantified rollout, so its gap depends on the November 5 update. The next catalysts are the tender offer filing, final Wolfspeed loan terms and the Haemonetics call. None of these outcomes is guaranteed, and any single filing can change the picture quickly.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...